Enhancement of therapeutic efficacy of aclarubicin against lymph node metastases using a new dosage form: aclarubicin adsorbed on activated carbon particles.

Abstract

Seven days after a subcutaneous inoculation of 5 x 10(5) P388 leukemia cells into the foot pad of the left hind paw of donor mouse, aclarubicin (0.2 mg/kg body weight) was injected subcutaneously into the hind paw of the opposite foot pad in the form of ACR-CH or aclarubicin aqueous solution. On day 10, the left popliteal and the lower para-aortic lymph nodes taken from each donor were transferred intraperitoneally to a normal recipient mouse. The combined survival time of recipients and the viable P388 leukemia cell number in popliteal and para-aortic lymph nodes were estimated with a calibration formula. Our results showed that the survival curve of recipients given ACR-CH was statistically improved compared with that of other treatment groups.

• Authors: C Sakakura, T Takahashi, K Sawai, A Hagiwara, M Ito, S Shobayashi, S Sasaki, K Ozaki, M Shirasu
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 3 Issue 3 Pg. 233-6 (Jun 1992) ISSN: 0959-4973 [Print] England
• PMID: 1525403 (Publication Type: Journal Article)

Chemical References

• Charcoal
• Aclarubicin

Topics

• Aclarubicin (administration & dosage, pharmacokinetics, therapeutic use)
• Animals
• Charcoal
• Leukemia P388 (complications, drug therapy)
• Lymph Nodes (pathology)
• Lymphatic Metastasis (pathology, prevention & control)
• Male
• Mice
• Mice, Inbred Strains